Response to treatment. Rates of complete response (CR) and partial response (PR) (A) and rates of measurable residual disease (MRD) negativity (MRD negative, 10⁻⁴; MRD intermediate, ≥10⁻⁴ and <10⁻²; MRD positive, ≥10⁻²) in peripheral blood (B) and bone marrow (C) 3 months after completion of treatment, according to treatment with ClbG or VenG and according to CKT or NCKT status. MRD rates are reported in the intention-to-treat population and 3 months after completion of treatment; therefore, patients who progressed before this time point were censored at last tumor assessment, and those with missing sample were reported as no sample/not evaluable.